Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468143 · ClinicalTrials.gov registry record · Phase 4
A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
A Phase 4 study of Attention Deficit Hyperactivity Disorder, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT00468143 is a Phase 4 study of Attention Deficit Hyperactivity Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 62 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00468143, a Phase 4 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to compare Adderall ® and Adderall XR ® in terms of their effectiveness and side effects for the treatment of ADHD in adults.
Conditions Studied
Interventions
- DRUG Adderall ® Immediate Release
- DRUG Adderall XR ®
Study Locations (1)
New York
- VANYHHS - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468143
The ClinicalTrials.gov registry entry for NCT00468143 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (70% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Adderall ® Immediate Release is the first listed.
NCT00468143 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00468143 about?
NCT00468143 is a clinical study titled "A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall". The purpose of this pilot study is to compare Adderall ® and Adderall XR ® in terms of their effectiveness and side effects for the treatment of ADHD in adults.
What is the current status of trial NCT00468143?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2007-08. Estimated completion is 2009-01.
What conditions does trial NCT00468143 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00468143?
The interventions under investigation include: Adderall ® Immediate Release (DRUG), Adderall XR ® (DRUG).
Who is sponsoring clinical trial NCT00468143?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00468143 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
R61/33 - VR Study Phase 4
RECRUITING · Phase 4
-
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
RECRUITING · Phase 4
-
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
RECRUITING · Phase 4
-
Stimulant Effects on Disruptive Behavior
RECRUITING · Phase 4
-
Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.